Cataract surgery continues to improve across Europe
A total of 363,039 cataract surgeries performed in 12 European countries in 2024 have been recorded in the European Registry of Quality Outcomes for Cataract and Refractive Surgery… read more.
A total of 363,039 cataract surgeries performed in 12 European countries in 2024 have been recorded in the European Registry of Quality Outcomes for Cataract and Refractive Surgery… read more.
Redness and pain at the injection site, fever, fatigue or headaches: vaccines can cause side effects, but their frequency and severity vary considerably from person to person. Why?… read more.
Novo Nordisk announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo’s next innovation… read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF (320/28.8/10μg)) has been approved in the European Union (EU) as a maintenance treatment for asthma in patients 12… read more.
Differences in how palliative care and oncology teams work together may help explain variation in end-of-life outcomes for patients with cancer, according to a multicentre qualitative study published… read more.
A common and often overlooked nutrient deficiency may play a bigger role in pregnancy outcomes than previously recognized. In a recent analysis published in the Journal of Perinatology,… read more.
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label… read more.
People with atrial fibrillation have signs of the condition in the retinas of their eyes that can be detected as early as four years before diagnosis, finds a… read more.
Artificial intelligence (AI) scribes can reduce the time physicians spend documenting patient visits by 69.1% during simulated primary care appointments, according to research led by University of Toronto PhD student LaShawn Murray. The… read more.
AbbVie has presented new real-world data on VRAYLAR® (cariprazine) at Psych Congress 2026 in New Orleans, including results from two prospective observational studies in major depressive disorder (MDD)… read more.
31 August 2026 – BeOne Medicines Ltd. announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab), in combination… read more.
A five-year, $3.4 million grant from the National Institutes of Health is powering work by an interdisciplinary team of researchers at The University of Texas at Dallas investigating… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.